Mpex Pharmaceuticals names new chief business officer

At Mpex Mr Wiggins will be focusing on commercial planning and business development activities related to the company’s lead product, MP-376. MP-376 is an inhaled antibiotic which is being developed for use as a maintenance therapy for the prevention of exacerbations in cystic fibrosis and chronic obstructive pulmonary disease.

Mr Wiggins comes to Mpex from Biogen Idec, where he most recently served as executive vice president of business development, and was a member of the executive committee.

Daniel Burgess, president and CEO of Mpex, said: “Mark’s background in the industry spearheading highly successful deals and partnerships is impressive and we are delighted to have him join Mpex. His deep experience in marketing will be key to us as we move towards commercialization with MP-376 and his expertise in structuring and managing complex collaborations will be invaluable as we are evaluating strategic commercialization options.”